Trusted by 8,000+ of the world’s largest enterprises


What the SuperAnalyst big pharma earnings dashboard shows
One dashboard that takes you from the big picture to each company’s results, with four views and eight company pages.
- Overview. The quarter on one screen: who grew fastest, who stalled, and how full-year guidance moved, with a five-quarter revenue view across all eight companies.
- Earnings & Guidance. Headline results and FY26 guidance side by side, plus a clear read on how acquired IPR&D charges distort EPS, so an EPS cut isn’t mistaken for weak performance.
- Growth Drivers. Winners and decliners by therapy class, from obesity and immunology to oncology and vaccines, showing where volume, pricing, new launches, and patent expiries are moving the numbers.
- Competitive Read-Through. What each company’s quarter means for everyone else, across obesity, immunology, and oncology, with the signals worth watching next.
- Company tabs. A focused view for each of the eight reporters: Lilly, Novo Nordisk, Merck, Pfizer, AstraZeneca, Johnson & Johnson, AbbVie, and Bristol Myers Squibb.
